Competitive but not allosteric mTOR kinase inhibition enhances tumor cell radiosensitivity

Translational Oncology

Volumn 6, Issue 3, 2013, Pages 355-362

  Hayman, Thomas J ^a,b   Kramp, Tamalee ^b   Kahn, Jenna ^b,c   Jamal, Muhammad ^b   Camphausen, Kevin ^b   Tofilon, Philip J ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO [3, 4 D] PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; FEMALE; FIBROBLAST CULTURE; GROWTH CURVE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IRRADIATION; MOUSE; NEOPLASM; NONHUMAN; RADIOSENSITIVITY; RADIOSENSITIZATION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84878715992     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13163     Document Type: Article

References (32)

1. Kumaraswamy S, Chinnaiyan P, Shankavaram UT, Lu X, Camphausen K, and Tofilon PJ (2008). Radiation-induced gene translation profiles reveal tumor type and cancer-specific components. Cancer Res 68, 3819-3826.
2. Lu X, de la Pena L, Barker C, Camphausen K, and Tofilon PJ (2006). Radiationinduced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes. Cancer Res 66, 1052-1061.
3. Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, and Tofilon PJ (2012). Translation initiation factor eIF4E is a target for tumor cell radiosensitization. Cancer Res 72, 2362-2372.
4. Laplante M and Sabatini DM (2012). mTOR signaling in growth control and disease. Cell 149, 274-293.
5. Sonenberg N and Hinnebusch AG (2009). Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731-745.
6. Zoncu R, Efeyan A, and Sabatini DM (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21-35.
7. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, et al. (2010). AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-298.
8. Guertin DA and Sabatini DM (2007). Defining the role of mTOR in cancer. Cancer Cell 12, 9-22.
9. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, and Ramon y Cajal S (2007). 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 67, 7551-7555.
10. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, and Bouscary D (2012). PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 14, 129-138.
11. Benjamin D, Colombi M, Moroni C, and Hall MN (2011). Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10, 868-880.
12. Hsieh AC and Ruggero D (2010). Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 16, 4914-4920.
13. Choo AY and Blenis J (2009). Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8, 567-572.
14. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, and Shokat KM (2009). Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7, e38.
15. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM, and Ruggero D (2010). Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17, 249-261.
16. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, and Gray NS (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284, 8023-8032.
17. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, et al. (2010). Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 70, 621-631.
18. Choo AY, Yoon SO, Kim SG, Roux PP, and Blenis J (2008). Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 105, 17414-17419.
19. Albert JM, Kim KW, Cao C, and Lu B (2006). Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 5, 1183-1189.
20. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, and Hamstra DA (2009). Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res 15, 589-596.
21. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, and Pommier Y (2008). γH2AX and cancer. Nat Rev Cancer 8, 957-967.
22. Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, Barton O, and Jeggo PA (2010). γH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle 9, 662-669.
23. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, and Lu B (2006). Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66, 10040-10047.
24. Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, Chang JK, Ampil F, Glass J, and Nathan CO (2009). Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 8, 2255-2265.
25. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, and Sarkaria JN (2002). Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62, 7291-7297.
26. Rosenzweig KE, Youmell MB, Palayoor ST, and Price BD (1997). Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 3, 1149-1156.
27. Hsieh AC, Truitt ML, and Ruggero D (2011). Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer 105, 329-336.
28. Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, Pollak M, and Sonenberg N (2012). Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci USA 109, 8977-8982.
29. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, et al. (2012). The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55-61.
30. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, and Schmidt-Ullrich RK (2002). Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21, 4032-4041.
31. Li H, Lin J, Wang X, Yao G, Wang L, Zheng H, Yang C, Jia C, Liu A, and Bai X (2012). Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat 134, 1057-1066.
32. National Library of Medicine, Bethesda MD (2000).